logo
Crashing into an asteroid creates chaotic space boulders

Crashing into an asteroid creates chaotic space boulders

Yahoo09-07-2025
In the almost three years since NASA proved that it could successfully deflect an asteroid, we've learned a lot about these space rocks. The September 2022 collision of a spacecraft into the asteroid moon Dimorphos completely changed the space rock's orbit. However, this groundbreaking test also showed smashing into an asteroid can trigger a barrage of boulders. The resulting chunks of rock carried more than three times the momentum of the spacecraft that crashed into Dimorphos. The ejected boulders created forces in unexpected directions that could complicate other attempts to deflect an asteroid, according to a study published this month in the Planetary Science Journal.
'We succeeded in deflecting an asteroid, moving it from its orbit,' study co-author and University of Maryland astronomer Tony Farnham said in a statement. 'Our research shows that while the direct impact of the DART spacecraft caused this change, the boulders ejected gave an additional kick that was almost as big. That additional factor changes the physics we need to consider when planning these types of missions.'
The team used images taken by LICIACube, a small Italian spacecraft that observed DART's aftermath. They tracked 104 boulders ranging from 0.2 to 3.6 meters (about half a foot to 11 feet) in radius as they shot across space away from Dimorphos at speeds up to 52 meters per second (116 miles per hour). Using those images, the astronomers determined the three-dimensional locations and velocities of the ejected rocks.
'We saw that the boulders weren't scattered randomly in space,' Farnham said. 'Instead, they were clustered in two pretty distinct groups, with an absence of material elsewhere, which means that something unknown is at work here.'
[ Related: 5 ways we know DART crushed that asteroid (but not literally). ]
The largest debris cluster they studied contains about 70 percent of the objects measured in the study. It was ejected south of the asteroid at high velocities and shallow angles. The authors believe that these ejected boulders likely came from specific sources. One source could be the larger boulders on Dimorphos that were shattered by DART's solar panels in the seconds before the main body of the car-sized spacecraft hit its surface.
'DART's solar panels likely hit two big boulders, called Atabaque and Bodhran, on the asteroid,' added study co-author and astronomer Jessica Sunshine. 'Evidence suggests that the southern cluster of ejected material is probably made up of fragments from Atabaque, a 3.3-meter-radius boulder.'
Sunshine served as deputy principal investigator for the NASA Deep Impact mission to probe the surface of Comet P/Tempel 1. She compared DART's results with Deep Impact's, noting that the surface features and target composition of the space rock fundamentally shape the impact outcomes.
'Deep Impact hit a surface that was essentially very small, uniform particles, so its ejecta was relatively smooth and continuous,' Sunshine explained. 'And here, we see that DART hit a surface that was rocky and full of large boulders, resulting in chaotic and filamentary structures in its ejecta patterns. Comparing these two missions side-by-side gives us this insight into how different types of celestial bodies respond to impacts, which is crucial to ensuring that a planetary defense mission is successful.'
Additionally, the momentum from the DART impact's ejected boulders was mostly perpendicular to the spacecraft's trajectory. This indicates that it could have tilted Dimorphos' orbital plane by up to one degree–potentially sending it tumbling into space. Understanding the effect that this boulder debris has will be key to the European Space Agency's Hera mission, which will arrive at the Didymos-Dimorphos system in 2026.
'Data gathered from LICIACube provides additional perspectives on impact events, especially as DART was originally designed to solely rely on Earth-based observations,' Farnham said. 'Hera will do the same by giving us another direct view of the impact's aftermath, relying on the predictions we've made using data gathered from DART.'
Farnham notes that these perspectives and close-up images from LICIACube gave the DART team crucial information that would have been impossible to detect from Earth. This includes the data on the asteroid boulders themselves. This new study suggests the importance of considering all of these variables when planning future asteroid deflection missions.
'If an asteroid was tumbling toward us, and we knew we had to move it a specific amount to prevent it from hitting Earth, then all these subtleties become very, very important,' Sunshine added. 'You can think of it as a cosmic pool game. We might miss the pocket if we don't consider all the variables.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?
RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?

Yahoo

time18 minutes ago

  • Yahoo

RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?

The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally funded mRNA vaccine development. This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said. "We reviewed the science, listened to the experts, and acted," Secretary Robert F. Kennedy Jr. said in a press release on Tuesday. "The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." MORE: What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny Infectious disease experts told ABC News that mRNA technology has been very successful in preventing severe disease, hospitalization and deaths, especially during the COVID-19 pandemic, potentially affecting our preparedness for future pandemics. Ending mRNA vaccine development may also squash enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. "It's an excellent technology. It saved millions of lives and did it in a remarkably safe manner," Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told ABC News. "I think it's an unscientific move, a move that goes against existing science." Affecting future pandemic preparedness Last year, the federal government awarded Moderna $176 million to help expedite the development of an mRNA-based bird flu vaccine. Earlier this year, the vaccine manufacturer received an additional $590 million to speed up the development. However, in its press release, the HHS said it was cancelling the award, which has been issued by the Biomedical Advanced Research and Development Authority, to Moderna and the University of Texas Medical Branch. Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, told ABC News the wind-down is a blow to pandemic preparedness. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly. "The message to the companies will clearly be that they can no longer rely on the U.S. government for supporting any mRNA vaccine work, which is unfortunate, or even tragic, because the mRNA platform is one of the few that we have for pandemic threats in terms of something that we can make a vaccine for very quickly," he said. "So what, what Mr. Kennedy's and HHS' actions are doing is weakening our pandemic preparedness and weakening our biosecurity." The HHS also said it was terminating contracts with Emory University and Tiba Biotech. Researchers had been working on using mRNA technology to develop a nasal influenza vaccine. Emory has also been working on a dry powder inhaled mRNA-based treatment for influenza and COVID with TFF Pharmaceuticals, funded by BARDA. It's unclear if this is one of the 22 contracts that have been canceled. MORE: What to know about the next generation of COVID-19 vaccines Hotez said COVID-19 and influenza can have very severe consequences and that it's incorrect for Kennedy to mischaracterize them as harmless upper respiratory infections. "COVID and flu are not [only] upper respiratory infections," he said. "The reason we develop vaccines for COVID and flu is because they cause systemic illness and lower respiratory infections and cardiovascular illness. … This is part of the anti-vaccine playbook, to diminish the severity of the illness, and to say something like influenza or COVID is an upper respiratory infection, it's just very, very misleading." Cancer vaccines, HIV treatments mRNA technology has also been hailed as a potential vector for providing personalized cancer treatments and protection against HIV transmission. In February, a small preliminary study published in the journal Nature found a personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery. Additionally, a University of Florida study found an experimental mRNA vaccine paired with anticancer drugs boosted an anti-tumor response. Meanwhile, earlier this month, an early-stage clinical trial found two mRNA vaccine candidates triggered a strong immune response against HIV. Results from the trial showed that 80% of participants who received one of two vaccine candidates produced antibodies. Although antiretroviral therapy has been the standard treatment for HIV infection, and is effective in preventing transmission, it is hard to scale up worldwide due to its costs, making mRNA vaccines to be anti-HIV vaccine strategy, researchers from the U.S., Germany and Romania wrote in a commentary in June 2022. It's unclear if any of the BARDA contracts are specifically for cancer vaccines or HIV vaccine development, but Hotez said the real damage is denigrating mRNA technology. "What he's done is he's caused uncertainty among the American people about the safety and effectiveness of mRNA for any condition, including cancer," he said. "And in fact, mRNA technology is probably the most exciting technology we have now for cancer and also other non-communicable illnesses. … Even though he may not be canceling any cancer vaccine contracts through BARDA, it may have collateral deleterious in terms of squashing enthusiasm for the technology." Offit added that mRNA is not brand-new technology. mRNA was discovered independently by two teams in 1961, including French and American molecular biologists. Breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. This makes the technology primed for being used in other avenues, such as cancer vaccines, Offit said. "We now know a lot about mRNA," he said. "We know a lot about its safety. We know a lot about its safety in young children, including babies. We know a lot about it regarding gene therapy. We know a lot about this safety in terms of pregnant people, where that's often not the case with new technology." Offit went on, "So you have this background of information that enables you to move forward in a number of areas, involving babies or involving pregnant women. But there was an attempt by this administration to squelch that, to sit on all that for no good reason other than a political reason." Solve the daily Crossword

Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%

Yahoo

time18 minutes ago

  • Yahoo

Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 16% year on year to $811.1 million. The company's full-year revenue guidance of $3.15 billion at the midpoint came in 1.7% above analysts' estimates. Its non-GAAP profit of $0.22 per share was significantly above analysts' consensus estimates. Is now the time to buy Exact Sciences? Find out in our full research report. Exact Sciences (EXAS) Q2 CY2025 Highlights: Exact Sciences will pay $75 million in cash (plus up to $700 million in additional payments) to secure the rights to Freenome's blood-based screening tools for colorectal cancer. Exact will also pay royalties up to 10% and $20 million annually for the next three years in joint R&D costs Revenue: $811.1 million vs analyst estimates of $773.1 million (16% year-on-year growth, 4.9% beat) Adjusted EPS: $0.22 vs analyst estimates of $0.05 (significant beat) Adjusted EBITDA: $138.2 million vs analyst estimates of $108.7 million (17% margin, 27.2% beat) The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.10 billion, a 1.8% increase EBITDA guidance for the full year is $465 million at the midpoint, above analyst estimates of $437.4 million Operating Margin: -0.3%, up from -3.8% in the same quarter last year Free Cash Flow Margin: 5.8%, down from 10.2% in the same quarter last year Constant Currency Revenue rose 16% year on year (12.4% in the same quarter last year) Market Capitalization: $8.93 billion 'The Exact Sciences team continues to build momentum, advancing our mission through earlier detection,' said Kevin Conroy, chairman and CEO. Company Overview With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ:EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test. Revenue Growth A company's long-term performance is an indicator of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Exact Sciences's 21.1% annualized revenue growth over the last five years was excellent. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Exact Sciences's annualized revenue growth of 13% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. We can better understand the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 13.3% year-on-year growth. Because this number aligns with its normal revenue growth, we can see that Exact Sciences has properly hedged its foreign currency exposure. This quarter, Exact Sciences reported year-on-year revenue growth of 16%, and its $811.1 million of revenue exceeded Wall Street's estimates by 4.9%. Looking ahead, sell-side analysts expect revenue to grow 11.8% over the next 12 months, similar to its two-year rate. Despite the slowdown, this projection is noteworthy and indicates the market is forecasting success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes. Although Exact Sciences broke even this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average operating margin of negative 29.8% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Exact Sciences's operating margin rose by 29.2 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company's margin has decreased by 16.6 percentage points on a two-year basis. If Exact Sciences wants to pass our bar, it must prove it can expand its profitability consistently. Exact Sciences's operating margin was negative 0.3% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although Exact Sciences's full-year earnings are still negative, it reduced its losses and improved its EPS by 33.1% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, Exact Sciences reported adjusted EPS at $0.22, up from negative $0.06 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Exact Sciences's full-year EPS of negative $0.33 will flip to positive $0.73. Key Takeaways from Exact Sciences's Q2 Results Exact Sciences will pay $75 million in cash and make up to $700 million in additional payments to secure the rights to Freenome's current and future blood-based screening tools for colorectal cancer. Exact will also pay sales royalties up to 10% and $20 million annually for the next three years in joint research and development costs. So do we think Exact Sciences is an attractive buy at the current price? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CBS host warns Trump admin plans for moon base could usher in new age of space colonialism
CBS host warns Trump admin plans for moon base could usher in new age of space colonialism

New York Post

time19 minutes ago

  • New York Post

CBS host warns Trump admin plans for moon base could usher in new age of space colonialism

CBS News host Vladimir Duthiers questioned the Trump administration's plan to establish a base on the moon and drew parallels to Earth's history of colonialism. On 'CBS Mornings Plus' on Wednesday, Duthiers and co-host Adriana Diaz discussed the White House calling for more human space exploration and administration plans to build a nuclear reactor on the moon to precede an eventual U.S. lunar base with astrophysicist Neil deGrasse Tyson. Advertisement Diaz asked if it was 'inevitable that we're going to have to go to the moon and try to colonize the Moon?' Tyson said that the United States is being 'reactive' in a race to the moon with China, and stated, to the laughter of the panel, that he does not want to 'live on the moon.' But Duthiers questioned if colonizing the moon was a good idea. 'We know how the age of colonialism worked on this planet,' the host said. 'Should we be trying to colonize and saying that there's a keep-out zone that no other countries can participate in having?' Advertisement Tyson replied by pointing out that it would be difficult to colonize an area that does not have people. 3 Duthiers questioned if it was a good idea to colonize the moon. CBS 3 United States astronaut Buzz Aldrin salutes the American flag on the surface of the Moon after he and fellow astronaut Neil Armstrong became the first men to land on the Moon during the Apollo 11 space mission July 20, 1969. REUTERS 'Well, the — the real problem with the colonization history in Western civilization is that there were people already there,' Tyson said. Advertisement Duthiers and Diaz agreed, and Tyson added that 'there are no moon beings that were displaced as far as we know.' Tyson later criticized administration plans to decrease funding to NASA. 3 Tyson said that the moon would be difficult to colonize because no one lives there. CBS 'What's not on brand is to cut science programs, not only in NASA, but across the board, and then say, we want to excel in this one spot,' Tyson said. Advertisement 'Well, in the 1960s, science was a major investment profile of the United States,' he continued. 'And by the way, it's not on brand even for Republicans, because Republican administrations since the Second World War have had a higher annual increase, average annual increase, in the science budget than even the Democrats.' 'So Trump's decision to cut science is not on brand for even being a Republican,' Tyson added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store